ライフサイエンスコーパス: pneumococcal conjugate vaccine

1 wi, in 2009-2011, before the introduction of pneumococcal conjugate vaccine.

2 was used to study the impact of the 7-valent pneumococcal conjugate vaccine.

3 No benefit was seen after pneumococcal conjugate vaccine.

4 protein-specific IgG responses to a soluble pneumococcal conjugate vaccine.

5 se with serotypes not covered by heptavalent pneumococcal conjugate vaccine.

6 effect was not observed using purified PS or pneumococcal conjugate vaccine.

7 fections since licensure of the seven-valent pneumococcal conjugate vaccine.

8 1% decrease), age-groups targeted to receive pneumococcal conjugate vaccine.

9 following a clinical trial of a seven-valent pneumococcal conjugate vaccine.

10 body responses of patients undergoing HCT to pneumococcal conjugate vaccine.

11 serotypes that are included in the 10-valent pneumococcal conjugate vaccine.

12 f serogroup C), and documented the impact of pneumococcal conjugate vaccine.

13 , >75% being of serotypes covered by current pneumococcal conjugate vaccines.

14 ed to prevent, as has already been seen with pneumococcal conjugate vaccines.

15 as an immunogenic carrier protein in future pneumococcal conjugate vaccines.

16 valuation of immunization regimens involving pneumococcal conjugate vaccines.

17 Pneumococcal conjugate vaccine 10 (PCV10) and pneumococc

18 neumococcal conjugate vaccine 10 (PCV10) and pneumococcal conjugate vaccine 13 (PCV13), are used in c

19 valuating the effectiveness of the 13-valent pneumococcal conjugate vaccine (2012-2016) to prevent al

20 Serotypes in the 7-valent pneumococcal conjugate vaccine (4, 6B, 9V, 14, 18C, 19F,

21 the 7 states had received at least 1 dose of pneumococcal conjugate vaccine; 43% of white and 39% of

22 e (HD) patients were immunized with 7-valent pneumococcal conjugate vaccine (7-OMPC) followed by one

23 rial colonization compared with the 7-valent pneumococcal conjugate vaccine (7vCRM) in young children

24 t publications found, most used the 7-valent pneumococcal conjugate vaccine (7vCRM).

25 nticapsular antibody responses to a 7-valent pneumococcal conjugate vaccine (7VPnC) were measured in

26 ctive interventions are available, including pneumococcal conjugate vaccine and case management.

27 es for China; and to consider the effects of pneumococcal conjugate vaccine and rotavirus vaccine in

28 Rapid scale-up and widespread use of the pneumococcal conjugate vaccine and sustained use of the

29 More recent prevention measures such as the pneumococcal conjugate vaccine and universal screening o

30 cale studies of households, we estimate that pneumococcal conjugate vaccines and live attenuated rota

31 against 12 serotypes contained in 13-valent pneumococcal conjugate vaccine, and evaluated determinan

32 o estimate child mortality, effectiveness of pneumococcal conjugate vaccine, and immunisation rates.

33 V23 serotypes not contained in the 13-valent pneumococcal conjugate vaccine (AOR, 1.70; 95% CI, .30-9

34 PS- and protein-specific IgG responses to a pneumococcal conjugate vaccine are inhibited in ICOS(-/-

35 Pneumococcal conjugate vaccines are important for the pr

36 Pneumococcal conjugate vaccines are important tools in t

37 ed by a booster at 11 months and a 10-valent pneumococcal conjugate vaccine at 2, 4, and 11 months af

38 ge from a "3 + 0" infant schedule (13-valent pneumococcal conjugate vaccine at 2, 4, and 6 months) to

39 To understand and model the impact of pneumococcal conjugate vaccines at the population level,

40 ion of healthy infants, requiring 4 doses of pneumococcal conjugate vaccine (at 2, 4, 6, and 12-15 mo

41 lates were serotypes included in heptavalent pneumococcal conjugate vaccines currently being evaluate

42 m 769 children 2-30 months old in a 7-valent pneumococcal conjugate vaccine dosing trial.

43 rial in Adults the model-predicted 13-valent pneumococcal conjugate vaccine efficacy for preventing v

44 ian visits in which impact was attributed to pneumococcal conjugate vaccines, either as efficacy or e

45 re immunized with either 2 doses of 7-valent pneumococcal conjugate vaccine followed by 1 dose of 23-

46 Introduction of pneumococcal conjugate vaccine for children could affect

47 Following recommendation of a new 7-valent pneumococcal conjugate vaccine for children in October 2

48 Pneumococcal conjugate vaccine for infants has recently

49 ensing, in February 2000, of the heptavalent pneumococcal conjugate vaccine for young children.

50 A 13-valent pneumococcal conjugate vaccine has been studied in adult

51 Pneumococcal conjugate vaccines have been successful, bu

52 Pneumococcal conjugate vaccines have had unprecedented s

53 yte antigen A2 (arm A, n = 28) also received pneumococcal conjugate vaccine immunizations before and

54 Factors associated with pneumococcal conjugate vaccine immunogenicity have not b

55 The study was conducted before pneumococcal conjugate vaccine implementation in Israel.

56 sions occurred after the introduction of the pneumococcal conjugate vaccine in 2006: hospital admissi

57 following the introduction of the 13-valent pneumococcal conjugate vaccine in 2011.

58 upport recommendations for widespread use of pneumococcal conjugate vaccine in low-income and middle-

59 e nonvaccine serotypes after introduction of pneumococcal conjugate vaccine in the United States in 2

60 nce supporting the beneficial effects of the pneumococcal conjugate vaccines in children.

61 ed to perform a protective efficacy trail of pneumococcal conjugate vaccines in infants, among whom m

62 ublicly purchased meningococcal conjugate or pneumococcal conjugate vaccines in the private sector in

63 tes were not contained in PCV7 (the 7-valent pneumococcal conjugate vaccine), including 1 isolate tha

64 luded in the previously recommended 7-valent pneumococcal conjugate vaccine, including serotype 19A,

65 In response to the selective pressure of pneumococcal conjugate vaccine, increased asymptomatic c

66 roup 6 pneumococci, and investigated whether pneumococcal conjugate vaccine-induced serotype 6A and 6

67 Five of seven serotypes in the pneumococcal conjugate vaccine, introduced for infants i

68 d serotype distributions were observed after pneumococcal conjugate vaccine introduction at regional

69 en a decline in pneumococcal meningitis post-pneumococcal conjugate vaccine introduction in Senegal.

70 imens collected from Israeli children before pneumococcal conjugate vaccine introduction.

71 The multivalent pneumococcal conjugate vaccine is effective against both

72 istance with the introduction of heptavalent pneumococcal conjugate vaccine is likely to be partially

73 Pneumococcal conjugate vaccine is not only effective aga

74 The use of the pneumococcal conjugate vaccine is preventing disease in

75 niversal immunization of young children with pneumococcal conjugate vaccine, it is unclear whether th

76 Much of the efficacy of current pneumococcal conjugate vaccines lies in their ability to

77 ate vaccine, the recently licensed 13-valent pneumococcal conjugate vaccine may reduce the incidence

78 The introduction of pneumococcal conjugate vaccines necessitates continued m

79 y was to analyse the effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal

80 tine childhood vaccination using heptavalent pneumococcal conjugate vaccine, one concern has been the

81 cyte antigen A2 (arm B, n = 26) received the pneumococcal conjugate vaccine only.

82 tion of routine vaccination with heptavalent pneumococcal conjugate vaccine, overall invasive pneumoc

83 Four main processes determine pneumococcal conjugate vaccine (PCV) antibiotic-nonsusce

84 eplacement disease following introduction of pneumococcal conjugate vaccine (PCV) are attributable to

85 In contrast, among children immunized with pneumococcal conjugate vaccine (PCV) both before and aft

86 Immunization schedules with pneumococcal conjugate vaccine (PCV) differ among countr

87 Vaccinating children with pneumococcal conjugate vaccine (PCV) disrupts transmissi

88 approximately 30%-60% of episodes before the pneumococcal conjugate vaccine (PCV) era.

89 3 months after transplant, giving 3 doses of pneumococcal conjugate vaccine (PCV) followed by either

90 nths after transplant, giving three doses of pneumococcal conjugate vaccine (PCV) followed by either

91 The widespread use of pneumococcal conjugate vaccine (PCV) has brought about a

92 We investigated the impact of infant pneumococcal conjugate vaccine (PCV) immunization on pne

93 Pneumococcal conjugate vaccine (PCV) implementation has

94 e outbreaks have not been reported following pneumococcal conjugate vaccine (PCV) implementation.

95 The effect of 7-valent pneumococcal conjugate vaccine (PCV) in developed countr

96 dle-income countries to study the benefit of pneumococcal conjugate vaccine (PCV) in protecting again

97 Data on pneumococcal conjugate vaccine (PCV) indirect effects in

98 t in comparable settings.Fifteen years after pneumococcal conjugate vaccine (PCV) introduction and 5

99 Following pneumococcal conjugate vaccine (PCV) introduction in 201

100 ccine-type pneumococcal meningitis following pneumococcal conjugate vaccine (PCV) introduction.

101 epresented pneumococci from before and after pneumococcal conjugate vaccine (PCV) introductions and w

102 markedly declined following 7- and 13-valent pneumococcal conjugate vaccine (PCV) introductions world

103 Pneumococcal conjugate vaccine (PCV) is now recommended

104 e aimed to determine the effect of 13-valent pneumococcal conjugate vaccine (PCV) on colonization.

105 Universal pneumococcal conjugate vaccine (PCV) programs began in I

106 Universal pneumococcal conjugate vaccine (PCV) programs began in I

107 Reduced-dose pneumococcal conjugate vaccine (PCV) schedules are under

108 Reduced-dose pneumococcal conjugate vaccine (PCV) schedules are under

109 There was a significant reduction of pneumococcal conjugate vaccine (PCV) serotypes, from 44.

110 ey will need to consider whether to continue pneumococcal conjugate vaccine (PCV) use at full cost or

111 Pneumococcal conjugate vaccine (PCV) was introduced into

112 ined whether revaccination with the 7-valent pneumococcal conjugate vaccine (PCV) would enhance these

113 den data to support decisions on introducing pneumococcal conjugate vaccine (PCV).

114 New Zealand introduced pneumococcal conjugate vaccine (PCV)7 in June 2008, PCV1

115 ccal empyema (PPE) prior to licensure of the pneumococcal conjugate vaccine (PCV-7) in 2000.

116 cine group), all residents received 7-valent pneumococcal conjugate vaccine (PCV-7), while in another

117 ccal polysaccharide vaccine (PPV; n = 14) or pneumococcal conjugate vaccine (PCV; n = 11).

118 Pneumococcal conjugate vaccines (PCV) are highly protect

119 Pneumococci could evade pneumococcal conjugate vaccines (PCV) by modifying, muta

120 The full extent to which childhood pneumococcal conjugate vaccines (PCV) can indirectly red

121 Although the use of pneumococcal conjugate vaccines (PCV) has reduced the ov

122 lation-based studies assessing the impact of pneumococcal conjugate vaccines (PCV) on burden of pneum

123 Kenya introduced 10-valent pneumococcal conjugate vaccine (PCV10) among children <1

124 Zambia introduced a 10-valent pneumococcal conjugate vaccine (PCV10) in July 2013 usin

125 ess the effect of introduction of ten-valent pneumococcal conjugate vaccine (PCV10) on pneumonia mort

126 outine infant immunisation with a ten-valent pneumococcal conjugate vaccine (PCV10) using three prima

127 The 10-valent pneumococcal conjugate vaccine (PCV10) was introduced in

128 Nepalese infants receive ten-valent pneumococcal conjugate vaccine (PCV10) with a 1 month in

129 Ten-valent pneumococcal conjugate vaccine (PCV10), delivered at 6,

130 March 2010, Brazil introduced the ten-valent pneumococcal conjugate vaccine (PCV10), which was licens

131 Both the 10- and 13-valent pneumococcal conjugate vaccines (PCV10 and PCV13) induce

132 evaluating the immune response to 13-valent pneumococcal conjugate vaccine (PCV13) administration 4

133 ults (CAPiTA), the efficacy of the 13-valent pneumococcal conjugate vaccine (PCV13) against first epi

134 Five sites use 13-valent pneumococcal conjugate vaccine (PCV13) alone and four us

135 recommend a combined schedule of a 13-valent pneumococcal conjugate vaccine (PCV13) and PPSV23 (23-va

136 ompared with those included in the 13-valent pneumococcal conjugate vaccine (PCV13) and the remaining

137 llogeneic HSCT received 3 doses of 13-valent pneumococcal conjugate vaccine (PCV13) at 1-month interv

138 V-Hib) at 2, 3, and 4 months of age, and the pneumococcal conjugate vaccine (PCV13) at 2, 4, and 12 m

139 The impact of the 13-valent pneumococcal conjugate vaccine (PCV13) at the population

140 The cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) compared with 23-

141 icipants received DTaP-IPV-Hib and 13-valent pneumococcal conjugate vaccine (PCV13) concurrently, fol

142 dy describes the immunogenicity of 13-valent pneumococcal conjugate vaccine (PCV13) during and after

143 Therefore, vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-va

144 removal of one primary dose of the 13-valent pneumococcal conjugate vaccine (PCV13) from the existing

145 Among older adults, 13-valent pneumococcal conjugate vaccine (PCV13) has been found ef

146 The 13-valent pneumococcal conjugate vaccine (PCV13) has recently been

147 ugate vaccine (PCV7) in 2000 and a 13-valent pneumococcal conjugate vaccine (PCV13) in 2010.

148 Zimbabwe introduced 13-valent pneumococcal conjugate vaccine (PCV13) in 2012 using a 3

149 Cambodia introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in January 2015 u

150 Senegal introduced a 13-valent pneumococcal conjugate vaccine (PCV13) in October 2013,

151 occal conjugate vaccine (PCV7) and 13-valent pneumococcal conjugate vaccine (PCV13) in the childhood

152 d the safety and immunogenicity of 13-valent pneumococcal conjugate vaccine (PCV13) in this populatio

153 commenced the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) into the routine

154 In 2013, Burkina Faso introduced 13-valent pneumococcal conjugate vaccine (PCV13) into the routine

155 The impact of 13-valent pneumococcal conjugate vaccine (PCV13) introduction on t

156 The 13-valent pneumococcal conjugate vaccine (PCV13) is the only licen

157 In France, the switch from PCV7 to 13-valent pneumococcal conjugate vaccine (PCV13) occurred in June

158 The impact of 13-valent pneumococcal conjugate vaccine (PCV13) on pneumococcal m

159 are available on the impact of the 13-valent pneumococcal conjugate vaccine (PCV13) on pneumococcal o

160 The 13-valent pneumococcal conjugate vaccine (PCV13) protects against

161 In 2010, a 13-valent pneumococcal conjugate vaccine (PCV13) replaced a 7-vale

162 In 2010, a 13-valent pneumococcal conjugate vaccine (PCV13) replaced PCV7 in

163 In 2010, the 13-valent pneumococcal conjugate vaccine (PCV13) replaced PCV7.

164 In March 2010, 13-valent pneumococcal conjugate vaccine (PCV13) replaced the seve

165 estimate in relation to PPV23/non-13-valent pneumococcal conjugate vaccine (PCV13) serotype pneumoni

166 dual serotypes, one or both isolates were a pneumococcal conjugate vaccine (PCV13) serotype.

167 The 13-valent pneumococcal conjugate vaccine (PCV13) was designed to i

168 Efficacy of the 13-valent pneumococcal conjugate vaccine (PCV13) was inferred befo

169 rotype 19A-related infections, the 13-valent pneumococcal conjugate vaccine (PCV13) was initially int

170 In March 2010, a 13-valent pneumococcal conjugate vaccine (PCV13) was introduced to

171 .9% (12/43) (P = 0.004), after the 13-valent pneumococcal conjugate vaccine (PCV13) was introduced.

172 In 2010, 13-valent pneumococcal conjugate vaccine (PCV13) was licensed and

173 A second-generation 13-valent pneumococcal conjugate vaccine (PCV13) was licensed and

174 The 13-valent pneumococcal conjugate vaccine (PCV13) was licensed to r

175 (UAD) assay for 13 serotypes included in the pneumococcal conjugate vaccine (PCV13) was recently repo

176 In 2012/2013, a single dose of 13-valent pneumococcal conjugate vaccine (PCV13) was recommended f

177 enzae type b (Hib) vaccine and the 13-valent pneumococcal conjugate vaccine (PCV13) were introduced i

178 tlicensure safety surveillance for 13-valent pneumococcal conjugate vaccine (PCV13), comparing the ri

179 Following the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13), ST diversity inc

180 g programmatic introduction of the 13-valent pneumococcal conjugate vaccine (PCV13), there is residua

181 n (UAD) assay capable of detecting 13-valent pneumococcal conjugate vaccine (PCV13)-associated seroty

182 aused by serotypes included in the 13-valent pneumococcal conjugate vaccine (PCV13).

183 o 6 years old (vaccinated with the 13-valent pneumococcal conjugate vaccine [PCV13] as part of the Ex

184 s before and after the widespread use of the pneumococcal conjugate vaccine PCV7.

185 itis has decreased since the introduction of pneumococcal conjugate vaccine (PCV7 and PCV13).

186 tality during baseline (2000-2007), 7-valent pneumococcal conjugate vaccine (PCV7) (2008-2010), and P

187 Serotypes associated with 7-valent pneumococcal conjugate vaccine (PCV7) accounted for 25%

188 ties, following the introduction of 7-valent pneumococcal conjugate vaccine (PCV7) and 13-valent pneu

189 (PCV13) was licensed to replace the 7-valent pneumococcal conjugate vaccine (PCV7) based on serologic

190 outine infant immunisation with seven-valent pneumococcal conjugate vaccine (PCV7) began in the USA i

191 The introduction of heptavalent pneumococcal conjugate vaccine (PCV7) could reduce acqui

192 2001, a serious shortage of the heptavalent pneumococcal conjugate vaccine (PCV7) developed in 34 st

193 Australia introduced universal 7-valent pneumococcal conjugate vaccine (PCV7) from 2005, replace

194 Use of heptavalent protein-polysaccharide pneumococcal conjugate vaccine (PCV7) has been associate

195 Widespread use of 7-valent pneumococcal conjugate vaccine (PCV7) has led to signifi

196 Vaccination with heptavalent pneumococcal conjugate vaccine (PCV7) has significantly

197 pneumococcal carriage compared with 7-valent pneumococcal conjugate vaccine (PCV7) immunized children

198 in light of the introductions of a 7-valent pneumococcal conjugate vaccine (PCV7) in 2000 and a 13-v

199 Introduction of the heptavalent pneumococcal conjugate vaccine (PCV7) in 2000 reduced ma

200 he introduction of the pediatric heptavalent pneumococcal conjugate vaccine (PCV7) in 2000, but its e

201 Since the pediatric introduction of 7-valent pneumococcal conjugate vaccine (PCV7) in 2000, incidence

202 he US introduction of the pediatric 7-valent pneumococcal conjugate vaccine (PCV7) in 2000.

203 Infants in the UK were first offered a pneumococcal conjugate vaccine (PCV7) in 2006, given at

204 South Africa introduced 7-valent pneumococcal conjugate vaccine (PCV7) in April 2009 usin

205 bserved after the introduction of a 7-valent pneumococcal conjugate vaccine (PCV7) in childhood immun

206 The introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) in September 2006

207 Following introduction of 7-valent pneumococcal conjugate vaccine (PCV7) in the United Stat

208 tantially following introduction of 7-valent pneumococcal conjugate vaccine (PCV7) into national immu

209 The introduction of 7-valent pneumococcal conjugate vaccine (PCV7) into the U.S. chil

210 imed to determine the impact of the 7-valent pneumococcal conjugate vaccine (PCV7) on invasive pneumo

211 characterised the impact of the seven-valent pneumococcal conjugate vaccine (PCV7) on pneumococcal ca

212 from serotype 6A, the impact of the 7-valent pneumococcal conjugate vaccine (PCV7) on the carriage of

213 Widespread use of pneumococcal conjugate vaccine (PCV7) resulted in decrea

214 Non-7-valent pneumococcal conjugate vaccine (PCV7) serotypes other th

215 ndividual serotypes included in the 7-valent pneumococcal conjugate vaccine (PCV7) transmitted by the

216 en in Israel who were enrolled in a 7-valent pneumococcal conjugate vaccine (PCV7) trial.

217 nce were evaluated after 7 years of 7-valent pneumococcal conjugate vaccine (PCV7) use in US children

218 We assessed the impact of 12 years of pneumococcal conjugate vaccine (PCV7) use on pneumococca

219 In 2000, seven-valent pneumococcal conjugate vaccine (PCV7) was introduced in

220 In South Africa, a 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in

221 A heptavalent pneumococcal conjugate vaccine (PCV7) was licensed in 20

222 e following the introduction of seven-valent pneumococcal conjugate vaccine (PCV7) were associated wi

223 and and Wales recently replaced the 7-valent pneumococcal conjugate vaccine (PCV7) with its 13-valent

224 hether donor immunization with a heptavalent pneumococcal conjugate vaccine (PCV7) would elicit prote

225 Before the introduction of 7-valent pneumococcal conjugate vaccine (PCV7), invasive pneumoco

226 zard ratios (aHRs) for OM comparing 7-valent pneumococcal conjugate vaccine (PCV7)-era (2006-2010) an

227 allenge, even after introduction of 7-valent pneumococcal conjugate vaccine (PCV7).

228 monia (CAP) after implementation of 7-valent pneumococcal conjugate vaccine (PCV7).

229 onses induced by a 7-valent, polysaccharide, pneumococcal conjugate vaccine (PCV7).

230 pneumococcal, many can be prevented by PCVs.Pneumococcal conjugate vaccine (PCV7/PCV13) implementati

231 rriage after 0, 1, 2, or 3 doses of 7-valent pneumococcal conjugate vaccine (PCV7; Prevnar) in infanc

232 The 7-valent and 13-valent pneumococcal conjugate vaccines (PCV7 and PCV13, respect

233 whether introduction of the 7- and 13-valent pneumococcal conjugate vaccines (PCV7 and PCV13, respect

234 ) in the context of the 7, 10, and 13 valent pneumococcal conjugate vaccines (PCV7, PCV10, PCV13).

235 The 7-valent pneumococcal conjugated vaccine (PCV7) has affected the

236 Indirect effects of pediatric use of pneumococcal conjugate vaccines (PCVs) affect rates of a

237 tic limitations, the protection conferred by pneumococcal conjugate vaccines (PCVs) against pediatric

238 Pneumococcal conjugate vaccines (PCVs) are being used wo

239 Pneumococcal conjugate vaccines (PCVs) are highly effect

240 Pneumococcal conjugate vaccines (PCVs) are used in many

241 hildhood death, even though highly effective pneumococcal conjugate vaccines (PCVs) are used in natio

242 Introduction of pneumococcal conjugate vaccines (PCVs) has shown a marke

243 Introduction of pneumococcal conjugate vaccines (PCVs) has substantially

244 Pneumococcal conjugate vaccines (PCVs) have been introdu

245 Pneumococcal conjugate vaccines (PCVs) have demonstrated

246 titis media (OM) burden following rollout of pneumococcal conjugate vaccines (PCVs) have exceeded pre

247 Although pneumococcal conjugate vaccines (PCVs) have greatly redu

248 Pneumococcal conjugate vaccines (PCVs) have had a well-d

249 Pneumococcal conjugate vaccines (PCVs) have reduced pneu

250 Pneumococcal conjugate vaccines (PCVs) have significantl

251 Pneumococcal conjugate vaccines (PCVs) have substantiall

252 Pneumococcal conjugate vaccines (PCVs) have substantiall

253 The use of pneumococcal conjugate vaccines (PCVs) in children has a

254 neumonia associated with the introduction of pneumococcal conjugate vaccines (PCVs) in five countries

255 information is available about the effect of pneumococcal conjugate vaccines (PCVs) in low-income cou

256 The continuing impact of pneumococcal conjugate vaccines (PCVs) in regions with h

257 Use of pneumococcal conjugate vaccines (PCVs) in resource-poor

258 There are concerns that pneumococcal conjugate vaccines (PCVs) in sub-Saharan Af

259 The introduction of pneumococcal conjugate vaccines (PCVs) into childhood va

260 y in the United States after introduction of pneumococcal conjugate vaccines (PCVs) into the infant i

261 direct effects of childhood vaccination with pneumococcal conjugate vaccines (PCVs) is unknown.

262 Understanding the real-world effect of pneumococcal conjugate vaccines (PCVs) on pneumonia mort

263 Pneumococcal conjugate vaccines (PCVs) prevent vaccine s

264 Pneumococcal conjugate vaccines (PCVs) target only a few

265 e defined in relation to the introduction of pneumococcal conjugate vaccines (PCVs), before (2005- 20

266 e choice between the two currently available pneumococcal conjugate vaccines (PCVs), ten-valent PCV (

267 moniae, an important human pathogen, and the pneumococcal conjugate vaccines (PCVs), which target onl

268 of IPD, and trends after the introduction of pneumococcal conjugate vaccines (PCVs).

269 ined significantly since the introduction of pneumococcal conjugate vaccines (PCVs).

270 Pneumococcal conjugated vaccines (PCVs) impact on comple

271 Six pentavalent pneumococcal conjugate vaccines (Pn-CRM197) were evaluat

272 nts in Soweto, South Africa, that a 9-valent pneumococcal conjugate vaccine, PncCV, prevents 31% (95%

273 of age received 2, 3, or 4 doses of 7-valent pneumococcal conjugate vaccine (PnCRM7) or control vacci

274 Despite the success of the pneumococcal conjugate vaccine, pneumococcal pneumonia r

275 The seven-valent pneumococcal conjugate vaccine prevents invasive disease

276 Finally, the commercial pneumococcal conjugate vaccine, Prevnar, contained a TLR

277 The 7-valent pneumococcal conjugate vaccine protected HIV-infected ad

278 Pneumococcal conjugate vaccine serotypes 5, 18C, 19F, an

279 atitis C, 55.3% were infected with 13-valent pneumococcal conjugate vaccine serotypes and 82.8% with

280 ntile) to 91% (75th percentile) for 7-valent pneumococcal conjugate vaccine serotypes and from 58% to

281 (12 [39%]); however, in the latter years non-pneumococcal conjugate vaccine serotypes were more commo

282 P < .001) and was similar for non-13-valent pneumococcal conjugate vaccine serotypes with both high

283 om 58% to 63% for the 6 additional 13-valent pneumococcal conjugate vaccine serotypes.

284 Routine immunization with pneumococcal conjugate vaccines should substantially red

285 The development and licensing of pneumococcal conjugate vaccines that are safe and effect

286 CAP and for assessing the efficacy of future pneumococcal conjugate vaccines that are under developme

287 were immunized with 1 of the 3 experimental pneumococcal conjugate vaccines that contain 6B and 19F

288 ld be disrupted by vaccinating children with pneumococcal conjugate vaccines that reduced nasopharyng

289 occal serotypes not included in the 7-valent pneumococcal conjugate vaccine, the emergence of a drug-

290 Finally, in the era of the pneumococcal conjugate vaccine, the frequency of rrgC in

291 efore and after introduction of the 7-valent pneumococcal conjugate vaccine, the recently licensed 13

292 cross-reactive antibodies are elicited with pneumococcal conjugate vaccines, the memory cells for lo

293 older adults, since introducing a 13-valent pneumococcal conjugate vaccine to the paediatric immunis

294 Following introduction of the 7-valent pneumococcal conjugate vaccine to the United States, rat

295 We reanalyzed the 7-valent pneumococcal conjugate vaccine trial FinOM for preventio

296 he scenarios considered suggest that ceasing pneumococcal conjugate vaccine use would cause an increa

297 e immunogenicity of experimental multivalent pneumococcal conjugate vaccines varies with different po

298 When seven-valent pneumococcal conjugate vaccine was introduced in the USA

299 Pneumococcal conjugate vaccines will eventually be licen

300 Since the introduction of the pneumococcal conjugate vaccines with/without protein D o